<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793489</url>
  </required_header>
  <id_info>
    <org_study_id>3406</org_study_id>
    <nct_id>NCT05793489</nct_id>
  </id_info>
  <brief_title>Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin</brief_title>
  <official_title>Prospective Double Arm Randomized Trial for Patients With Multiple Brain Metastasis and/or Leptomeningeal Carcinomatosis: Comparison of WBRT Alone and WBRT Plus Silibinin (Sillbrain)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The occurrence of brain metastases (BMs) is increasing given the availability of a more&#xD;
      accurate radiological imaging such as MRI for detecting also small brain lesions and the most&#xD;
      effective systemic therapy able to control extracranial disease. Although, the new target&#xD;
      therapy and immunotherapy has proven to be effective on brain metastasis too, a subgroup of&#xD;
      patients shows prove themselves unresponsive to medical treatment. A further subgroup of&#xD;
      patients exhibit diffuse brain disease for the presence of multiple brain lesion (&gt;10 BMs) or&#xD;
      leptomeningeal carcinomatosis. Among these patients the most treatment employed is&#xD;
      represented by whole brain RT. Since the 1950s, whole-brain radiation therapy (WBRT) has been&#xD;
      the most widely used treatment for patients with multiple brain metastases, given its&#xD;
      effectiveness in palliation, widespread availability, and ease to delivery. However, the&#xD;
      median overall survival recorded is restricted to 3 months, on the average. A better&#xD;
      understanding of the molecular and cellular mechanisms underlying brain metastasis might be&#xD;
      expected to lead to improvements in the overall survival rate for these patients. Recent&#xD;
      studies have revealed complex interactions between metastatic cancer cells and their&#xD;
      microenvironment in the brain. Priego et al. describe that brain metastatic cells induce and&#xD;
      maintain the co-option of a pro-metastatic program driven by signal transducer and activator&#xD;
      of transcription 3 (STAT3) in a subpopulation of reactive astrocytes surrounding metastatic&#xD;
      lesions. In patients, active STAT3 in reactive astrocytes correlates with reduced survival&#xD;
      from diagnosis of intracranial metastases. Blocking STAT3 signaling in reactive astrocytes&#xD;
      reduces experimental brain metastasis from different primary tumor sources, even at advanced&#xD;
      stages of colonization. Silibinin (or silybin) is a natural polyphenolic flavonoid isolated&#xD;
      from seed extracts of the herb milk thistle (Silybum marianum). Silibinin has been shown to&#xD;
      impair STAT3 activation. Preclinical studies show that Silibinin has an anticancer effects in&#xD;
      vitro and in vivo.&#xD;
&#xD;
      Based on this background, the investigators designed a double arm randomized trial evaluating&#xD;
      the benefit of Silibinin (in the form of marketed supplement) associated to WBRT respect to&#xD;
      WBRT alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2023</start_date>
  <completion_date type="Anticipated">March 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective double arm randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Outcome will be evaluated in months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity in term of use of corticosteroid therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Outcome will be evaluated in term of use or not of corticosteroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Distant Failure (BDF)</measure>
    <time_frame>12 months</time_frame>
    <description>Outcome will be evaluated in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Outcome will be evaluated in months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <arm_group>
    <arm_group_label>WBRT + Silibinin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo WBRT concomitant to Silibinin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBRT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo WBRT alone, total dose of 30 Gy in 10 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Silibinin</intervention_name>
    <description>WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.&#xD;
Total dose and fractionation of WBRT: 30 Gy in 10 fractions.</description>
    <arm_group_label>WBRT + Silibinin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Histological or cytological confirmation of solid tumor malignancy&#xD;
&#xD;
          -  Clinical indication for whole brain radiotherapy&#xD;
&#xD;
          -  Karnofsky performance status (KPS) â‰¥60&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior WBRT&#xD;
&#xD;
          -  KPS &lt; 60&#xD;
&#xD;
          -  Diagnosis of Lymphoproliferative disease&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elena Clerici</last_name>
    <phone>0282247310</phone>
    <email>elena.clerici@humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Clerici, MD</last_name>
      <phone>+390282247310</phone>
      <email>elena.clerici@humanitas.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>April 11, 2023</last_update_submitted>
  <last_update_submitted_qc>April 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Metastases</keyword>
  <keyword>WBRT</keyword>
  <keyword>Silibinin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silybin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

